EMA’s human medicines committee (CHMP) has recommended authorising an adapted Comirnaty vaccine targeting the Omicron XBB.1.5 subvariant.
The
vaccine – known as Comirnaty Omicron XBB.1.5 – is to be used for
preventing COVID-19 in adults and children from 6 months of age. (...)
Nessun commento:
Posta un commento